Sharbat v. Iovance Biotherapeutics, Inc.

CourtDistrict Court, S.D. New York
DecidedMay 9, 2024
Docket1:20-cv-01391
StatusUnknown

This text of Sharbat v. Iovance Biotherapeutics, Inc. (Sharbat v. Iovance Biotherapeutics, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sharbat v. Iovance Biotherapeutics, Inc., (S.D.N.Y. 2024).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK SOLOMON SHARBAT, SOLOMON CAPITAL LLC, SOLOMON CAPITAL 401(K) TRUST, and SHELHAV RAFF, Plaintiffs, OPINION & ORDER – against – 20-cv-1391 (ER) IOVANCE BIOTHERAPEUTICS, INC. f/k/a LION BIOTECHNOLOGIES, INC. f/k/a GENESIS BIOPHARMA, INC., and MANISH SINGH, Defendants. RAMOS, D.J.: Solomon Sharbat, Solomon Capital LLC, Solomon Capital 401(K) Trust, and Shelhav Raff (collectively, “Plaintiffs”) brought this action against Iovance Biotherapeutics (“Iovance”) for the alleged breach of a finder’s fee agreement. Doc. 15 (First Am. Compl.). Following a successful motion for sanctions by Iovance that resulted in the dismissal of all other claims, Plaintiffs’ only remaining claims were for unjust enrichment and indemnity. Doc. 140 (Jan. 4, 2023 Op.) at 40–41. Iovance thereafter moved for summary judgment on those remaining claims (Doc. 184), which the Court granted (Doc. 209). Plaintiffs appealed.1 Doc. 222. Before the Court are Iovance’s (1) submissions for the amount of sanctions, (2) motion for attorney’s fees, and (3) motion to require Plaintiffs to post an appeal bond. Docs. 141, 213, 225. For the reasons set forth below, all three applications are granted.

1 Plaintiffs’ appealed the Court’s decisions granting Iovance’s motions for judgment on the pleadings, for sanctions, and summary judgment, as well as its denying Plaintiffs’ motion to compel and for reconsideration of the same. Although “the filing of a notice of appeal has jurisdictional implications, . . . notwithstanding a pending appeal, a district court retains residual jurisdiction over collateral matters, including claims for attorneys’ fees.” Tancredi v. Metro. Life Ins. Co., 378 F.3d 220, 225 (2d Cir. 2004) (internal citations omitted); accord Neroni v. Becker, 609 F. App’x 690, 692 (2d Cir. 2015). �e Court therefore retains jurisdiction for purposes of deciding the instant motions before the Court. I. BACKGROUND A. Factual Background Sharbat and Raff are in the business of helping corporate clients with fundraising, mergers, and strategic alliances, and making introductions to facilitate those ends. Doc. 188 ¶ 5. Sharbat held a Series 7 securities license until November 2012, when FINRA revoked the license and banned him from participating in the securities industry. Id. ¶ 7. No other plaintiff has ever been licensed to broker securities. Id. ¶¶ 6, 9. Solomon Capital is a limited liability company, and Solomon Capital 401(K) Trust is a qualified retirement trust, for which Sharbat is the trustee. Doc. 15 ¶¶ 4–5. It is not disputed that Solomon Capital and Solomon Capital 401(K) Trust are owned and controlled by Sharbat; they have no employees and conduct no business activities other than holding assets on Sharbat’s behalf. See Doc. 140 at 2. Iovance2 is a publicly traded biotechnology company focused on the development of cancer therapies. Doc. 188 ¶ 1. On June 15, 2012, it signed a contract with MBA Holdings, LLC (“MBA”) “to act as a finder to seek financing and other strategic relationships” by introducing investors to Iovance who would participate in planned equity financing (“the MBA Agreement”). Id. ¶ 10–11. Plaintiffs were neither direct parties to, nor intended beneficiaries of, the MBA Agreement, contrary to what Plaintiffs claimed. Doc. 140 at 24. Nor are Plaintiffs indemnified parties within the meaning of the MBA Agreement. Doc. 188 ¶¶ 24–25; see also Doc. 186-9 (MBA Agreement) § 4. Plaintiffs claimed that, beginning in 2012, they began to perform pursuant to the MBA Agreement to seek out investors for Iovance.3 Id. ¶ 15. Specifically, Plaintiffs claimed Sharbat introduced two investors who participated in a financing that closed in

2 In 2012, when the events at issue in this action occurred, the company was named Genesis Biopharma, Inc. Doc. 188 ¶ 2. On September 25, 2013, the company amended and restated its articles of incorporation, which changed the company’s name to Lion Biotechnologies, Inc. Id. ¶ 3. On June 27, 2017, the company changed its name again to Iovance Biotherapeutics, Inc. Id. ¶ 4. For the sake of simplicity, the Court here refers to the company as Iovance, regardless of its actual name at the time. 3 In their complaint, Plaintiffs alleged that MBA’s chief financial officer informed Sharbat and Raff that they could earn substantial fees by working alongside MBA to find investors for Iovance. Doc. 15 ¶¶ 28–29. November 2013: Joe Edelman of Perceptive Advisors and Wayne Rothbaum of Quogue Capital. Id. ¶ 18. But Raff admitted he never met or otherwise communicated with either Edelman or Rothbaum. Id. ¶ 16. Sharbat similarly admitted he never met either Edelman or Rothbaum, and his “only way of getting the deal to them” was by talking to another man, but he could not recall if that man was affiliated with either Edelman or Rothbaum. Doc. 186-6 (Dec. 16, 2021 Sharbat Dep. Tr.) at 183:18–185:9. Additionally, Sharbat acknowledged that Iovance’s former chief executive officer (“CEO”), Anthony Cataldo, had already been in contact with Edelman about investing in Iovance months before Sharbat’s alleged introduction. Id. at 186:14–187:4; see also Doc. 186-1 (Aug. 19, 2019 Sharbat Dep. Tr.) at 150:16–24. And, likewise, Iovance was introduced to Rothbaum by a mutual friend of Iovance’s then-CEO, Manish Singh, not by Sharbat. Doc. 187 (Manish Singh Decl.) ¶ 6; see also Doc. 187-1 (email from Richard Lin introducing Singh and Rothbaum to one another). Rothbaum thereafter introduced Edelman to Singh to convince Edelman to invest as well. Doc. 187 ¶ 7. B. Procedural History Plaintiffs filed this suit on September 27, 2019 in New York state court against Iovance and Singh. Doc. 1-1. On February 18, 2020, Iovance removed the case to this Court. Doc. 1. Plaintiffs amended their complaint on May 1, 2020. Doc. 15. Pursuant to that amended complaint, Plaintiffs brought claims for breach of contract, unjust enrichment, and indemnification against Iovance, as well as claims for fraud and conversion against Singh. Id. On May 22, 2020, Iovance moved to dismiss for lack of personal jurisdiction (Doc. 18), and, on June 19, 2020, Singh also moved to dismiss (Doc. 21). �e Court denied both motions on March 26, 2021. Doc. 29. Iovance and Singh answered on April 30, 2021. Doc. 37. Iovance and Singh moved for judgment on the pleadings pursuant to Rule 12(c) on May 26, 2021 (Docs. 42 and 44, respectively), and the Court granted both motions on January 5, 2022 (Doc. 92). As a result, all claims against Singh were dismissed, and the only claims remaining against Iovance were those for breach of contract on the MBA Agreement, unjust enrichment, and indemnification. Id. �e Court also denied Plaintiffs’ request for leave to file a second amended complaint on the basis that they did not exercise diligence or adequately explain why they could not have included the new allegations earlier. See id. at 23–25. On March 28, 2022, Sharbat, Solomon Capital, and Solomon Capital 401(K) Trust (collectively, “the Sharbat Parties”)—but not Raff—entered into an assignment agreement (“the Assignment”) with MBA and newly-formed MBA Sharbat Holdings Inc., a Wyoming corporation (“MBA Sharbat”). Doc. 111-6. �e Assignment provided that: MBA owns all right, title and interest in and to the benefits of [the MBA Agreement and that] in consideration of the services of the Sharbat Parties in assisting MBA in the performance of MBA’s ob- ligations under and pursuant to the MBA [Agreement], MBA agreed that it would pay [the] Sharbat Parties shares of the compensation due to MBA pursuant to the MBA [Agreement]. Id. at 2 (emphasis added).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Simmons v. New York City Transit Authority
575 F.3d 170 (Second Circuit, 2009)
Federal Deposit Insurance Corp. v. Dintino
167 Cal. App. 4th 333 (California Court of Appeal, 2008)
Campbell v. Scripps Bank
93 Cal. Rptr. 2d 635 (California Court of Appeal, 2000)
Blickman Turkus v. Mf Downtown Sunnyvale
76 Cal. Rptr. 3d 325 (California Court of Appeal, 2008)
Tri-Star Pictures, Inc. v. Unger
32 F. Supp. 2d 144 (S.D. New York, 1999)
Berry v. Deutsche Bank Trust Co. Americas
632 F. Supp. 2d 300 (S.D. New York, 2009)
Santisas v. Goodin
951 P.2d 399 (California Court of Appeal, 1998)
Cargill, Inc. v. Souza
201 Cal. App. 4th 962 (California Court of Appeal, 2011)
Adsani v. Miller
139 F.3d 67 (Second Circuit, 1998)
Renwick v. Bennett (In re Bennett)
298 F.3d 1059 (Ninth Circuit, 2002)
In re Petrobras Sec. Litig.
363 F. Supp. 3d 426 (S.D. Illinois, 2019)
In re Relativity Fashion, LLC
565 B.R. 50 (S.D. New York, 2017)
Neroni v. Becker
609 F. App'x 690 (Second Circuit, 2015)
Stillman v. Inservice America Inc.
838 F. Supp. 2d 138 (S.D. New York, 2011)
In re General Electric Co. Securities Litigation
998 F. Supp. 2d 145 (S.D. New York, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
Sharbat v. Iovance Biotherapeutics, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/sharbat-v-iovance-biotherapeutics-inc-nysd-2024.